
Safety of Recombinant Zoster Vaccine in Rheumatic Patients
New work presented at EULAR focuses on the RZV, which contains recombinant glycoprotein E – the major target of CD4+T-cells. The abstract describes the tolerability and safety of RZV in patients with inflammatory https://t.co/NS3h9CdGIU
Links:
17-06-2025